Nicholas J. Hathaway
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicholas J. Hathaway has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
- Bryan Greenhouse
Department of Medicine, University of California, San Francisco, USA
8 shared publications - Jeffrey A. Bailey
Brown University, Providence, USA
8 shared publications - Jessica Briggs
University of California, San Francisco
7 shared publications - Jonathan J. Juliano
University of North Carolina at Chapel Hill, Chapel Hill, USA
7 shared publications - Philip Rosenthal
UCSF
7 shared publications - Grant Dorsey
Department of Medicine, University of California San Francisco , San Francisco, California
6 shared publications
Latest Publications
- Open Access
Whole-genome characterization of Plasmodium falciparum population structure and drug resistance across Uganda and neighboring countries
Uganda has one of the world’s highest malaria burdens, but parasite population structure and connectivity have not been characterized nationally with whole-genome data. We analyzed 249 monoclonal Plasmodium falciparum genomes from 26 sentinel sites across Uganda in 2023 and compared them with publicly available genomes from five neighboring countries. Genetic diversity was high and differentiation low in Uganda, but identity-by-descent detected limited structure. This was most pronounced in the low-transmission southwest, where parasites shared ancestry and recent relatedness with isolates from western Tanzania. Selection scans identified signals at loci associated with resistance to artemisinins and their partner drugs, and to chloroquine and antifolates. The strongest signal was at PfPX1 where the PIN haplotype (L1222P, M1701I, D1705N) reached 70% prevalence nationwide, but selection was carried by PIN haplotypes that had additionally acquired D384A, largely confined to northern and eastern Uganda. A second substitution at the same codon, D384Y, formed a haplotype shared across the Tanzanian border. PfKelch13 variants were partitioned across multiple backgrounds, consistent with repeated independent emergence, and C469Y was enriched on the PfPX1 D384A-PIN background. These genomes provide a 2023 baseline for tracking potential mediators of drug resistance and support coordinated genomic surveillance across Uganda and its neighbors.
Open AccessWhole-genome characterization of Plasmodium falciparum population structure and drug resistance across Uganda and neighboring countries
Uganda has one of the world’s highest malaria burdens, but parasite population structure and connectivity have not been characterized nationally with whole-genome data. We analyzed 249 monoclonal Plasmodium falciparum genomes from 26 sentinel sites across Uganda in 2023 and compared them with publicly available genomes from five neighboring countries. Genetic diversity was high and differentiation low in Uganda, but identity-by-descent detected limited structure. This was most pronounced in the low-transmission southwest, where parasites shared ancestry and recent relatedness with isolates from western Tanzania. Selection scans identified signals at loci associated with resistance to artemisinins and their partner drugs, and to chloroquine and antifolates. The strongest signal was at PfPX1 where the PIN haplotype (L1222P, M1701I, D1705N) reached 70% prevalence nationwide, but selection was carried by PIN haplotypes that had additionally acquired D384A, largely confined to northern and eastern Uganda. A second substitution at the same codon, D384Y, formed a haplotype shared across the Tanzanian border. PfKelch13 variants were partitioned across multiple backgrounds, consistent with repeated independent emergence, and C469Y was enriched on the PfPX1 D384A-PIN background. These genomes provide a 2023 baseline for tracking potential mediators of drug resistance and support coordinated genomic surveillance across Uganda and its neighbors.
- Open Access
PfPHAST: Plasmodium falciparum Public Health Amplicon Sequencing Tool, a Streamlined Panel for Malaria Genomic Surveillance
Genomic tools can support malaria control policy through surveillance of Plasmodium falciparum populations, tracking antimalarial drug resistance, pfhrp2/3 deletions that compromise rapid diagnostic tests, and selection at the circumsporozoite protein (PfCSP) vaccine target, as well as through molecular correction of therapeutic efficacy studies (TES). Multiplex Amplicons for Drug, Diagnostic, Diversity, and Differentiation Haplotypes using Targeted Resequencing (MAD 4 HatTeR), a comprehensive amplicon sequencing panel covering up to 276 targets, supports these applications but is tailored to research rather than routine programmatic use. We developed P. falciparum Public Health Amplicon Sequencing Tool (PfPHAST), a 56-target derivative of MAD 4 HatTeR spanning drug resistance loci, pfhrp2 / 3 deletion, PfCSP genotyping, non-falciparum species identification, and 20 high-heterozygosity microhaplotype loci for TES classification. We compared PfPHAST and MAD 4 HatTeR using laboratory strain controls, including two-strain dilution series and a five-strain mixture, across parasite densities of 100 to 10,000 parasites/µL. At matched per-target depth, PfPHAST achieved a higher quality-control pass rate than MAD4HatTeR (94.4% versus 90.0%) and distributed reads more evenly across targets. The panels showed comparable recall and precision for drug resistance codons and microhaplotypes, reaching near-complete recall above 40% within-sample allele frequency (WSAF) at all densities, with reduced sensitivity for minor alleles below 10% WSAF at low parasite density in both panels. Observed and expected WSAF correlated strongly for both panels, and both resolved a five-strain polyclonal mixture, including a 5% minor strain. By concentrating sequencing capacity on targets of greatest programmatic relevance, PfPHAST offers a scalable, lower-cost alternative to comprehensive research panels without sacrificing performance on shared targets, complementing MAD 4 HatTeR for routine molecular malaria surveillance.
Open AccessPfPHAST: Plasmodium falciparum Public Health Amplicon Sequencing Tool, a Streamlined Panel for Malaria Genomic Surveillance
Genomic tools can support malaria control policy through surveillance of Plasmodium falciparum populations, tracking antimalarial drug resistance, pfhrp2/3 deletions that compromise rapid diagnostic tests, and selection at the circumsporozoite protein (PfCSP) vaccine target, as well as through molecular correction of therapeutic efficacy studies (TES). Multiplex Amplicons for Drug, Diagnostic, Diversity, and Differentiation Haplotypes using Targeted Resequencing (MAD 4 HatTeR), a comprehensive amplicon sequencing panel covering up to 276 targets, supports these applications but is tailored to research rather than routine programmatic use. We developed P. falciparum Public Health Amplicon Sequencing Tool (PfPHAST), a 56-target derivative of MAD 4 HatTeR spanning drug resistance loci, pfhrp2 / 3 deletion, PfCSP genotyping, non-falciparum species identification, and 20 high-heterozygosity microhaplotype loci for TES classification. We compared PfPHAST and MAD 4 HatTeR using laboratory strain controls, including two-strain dilution series and a five-strain mixture, across parasite densities of 100 to 10,000 parasites/µL. At matched per-target depth, PfPHAST achieved a higher quality-control pass rate than MAD4HatTeR (94.4% versus 90.0%) and distributed reads more evenly across targets. The panels showed comparable recall and precision for drug resistance codons and microhaplotypes, reaching near-complete recall above 40% within-sample allele frequency (WSAF) at all densities, with reduced sensitivity for minor alleles below 10% WSAF at low parasite density in both panels. Observed and expected WSAF correlated strongly for both panels, and both resolved a five-strain polyclonal mixture, including a 5% minor strain. By concentrating sequencing capacity on targets of greatest programmatic relevance, PfPHAST offers a scalable, lower-cost alternative to comprehensive research panels without sacrificing performance on shared targets, complementing MAD 4 HatTeR for routine molecular malaria surveillance.
- 15 September 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Parasite Strain Turnover and Mosquito Infectivity in Untreated Subpatent Malaria
Background: In settings where malaria transmission has declined, subpatent malaria due to low-density Plasmodium falciparum infection remains prevalent. Low-density parasitemia persisting over time may represent dynamic turnover of parasite genetic variants. Methods: We performed targeted parasite sequencing in 330 persons with asymptomatic malaria in Bagamoyo, Tanzania from 2018 to 2021. A subset of 286 with subpatent parasitemia (RDT-negative, PCR-positive) were followed over 4 weeks to examine outcomes and parasite genetic make-up within individuals in the absence of treatment. Infectiousness to mosquitoes was assessed using direct skin feeding assays. Results: Parasite diversity based on microhaplotypes at 4 hypervariable markers (CSP, AMA1, SERA2, TRAP) was high, with a mean of 1.7 (range 1–8) unique microhaplotypes per sampling. While roughly half of RDT-negative parasitemias were transient, in those with persistent subpatent carriage, parasite strain turnover was frequent, with 91% of those sampled 3 times showing new microhaplotypes at subsequent visits. Among the 28% (79/286) of subpatent carriers who developed RDT positivity within 4 weeks, 94% (15/16 with paired genotyping) were associated with turnover in the major haplotype in at least one marker, whereas persistence of the major haplotype was more common in those with persistent subpatent carriage. Infectiousness appeared to increase in those who developed patent malaria but not in those with persistent carriage. Conclusions: In coastal Tanzania, subpatent malaria is often transient while persistent carriage involves dynamically changing parasite variants and low-level infectivity to mosquitoes. Patent malaria with higher transmission potential develops in the setting of newly inoculated or ascendant genotypes.
- 15 September 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Parasite Strain Turnover and Mosquito Infectivity in Untreated Subpatent Malaria
Background: In settings where malaria transmission has declined, subpatent malaria due to low-density Plasmodium falciparum infection remains prevalent. Low-density parasitemia persisting over time may represent dynamic turnover of parasite genetic variants. Methods: We performed targeted parasite sequencing in 330 persons with asymptomatic malaria in Bagamoyo, Tanzania from 2018 to 2021. A subset of 286 with subpatent parasitemia (RDT-negative, PCR-positive) were followed over 4 weeks to examine outcomes and parasite genetic make-up within individuals in the absence of treatment. Infectiousness to mosquitoes was assessed using direct skin feeding assays. Results: Parasite diversity based on microhaplotypes at 4 hypervariable markers (CSP, AMA1, SERA2, TRAP) was high, with a mean of 1.7 (range 1–8) unique microhaplotypes per sampling. While roughly half of RDT-negative parasitemias were transient, in those with persistent subpatent carriage, parasite strain turnover was frequent, with 91% of those sampled 3 times showing new microhaplotypes at subsequent visits. Among the 28% (79/286) of subpatent carriers who developed RDT positivity within 4 weeks, 94% (15/16 with paired genotyping) were associated with turnover in the major haplotype in at least one marker, whereas persistence of the major haplotype was more common in those with persistent subpatent carriage. Infectiousness appeared to increase in those who developed patent malaria but not in those with persistent carriage. Conclusions: In coastal Tanzania, subpatent malaria is often transient while persistent carriage involves dynamically changing parasite variants and low-level infectivity to mosquitoes. Patent malaria with higher transmission potential develops in the setting of newly inoculated or ascendant genotypes.
- Open Access
- 15 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0036126
Sustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023–2024
The emergence and spread of drug resistance threaten malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Ten thousand thirty samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria and sequenced using the MAD 4 HatTeR panel and Illumina platforms; of these, 8,518 passed quality control and were analyzed. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y, and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.
- 15 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0036126
Open AccessSustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023–2024
The emergence and spread of drug resistance threaten malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Ten thousand thirty samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria and sequenced using the MAD 4 HatTeR panel and Illumina platforms; of these, 8,518 passed quality control and were analyzed. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y, and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.
- Top Cited PapersOpen Access
Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24
The emergence and spread of drug resistance threatens malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria, sequenced using the MAD 4 HatTeR panel and Illumina platforms. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.
Top Cited PapersOpen AccessSustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24
The emergence and spread of drug resistance threatens malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria, sequenced using the MAD 4 HatTeR panel and Illumina platforms. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.
- 13 February 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (6) , 1110-1119
Recurrent Plasmodium falciparum Parasitemia and Drug Resistance Mutations During Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda
Background: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine (IPTp-SP) is recommended during pregnancy in malaria-endemic countries. However, widespread resistance of Plasmodium falciparum to SP has compromised its efficacy, and the alternative dihydroartemisinin-piperaquine (DP) is under study. Potential selection of drug resistance is important. Methods: We sequenced 1377 samples collected from pregnant women enrolled in a trial comparing monthly SP, DP, and DP + SP for IPTp in Busia, Uganda and with asymptomatic parasitemia at the time of IPTp administration. We characterized known markers of drug resistance and assessed the 28-day cumulative risk of recurrent parasitemia, with genotyping to distinguish recrudescence from new infections. Results: Among 771 samples collected on the day IPTp was initiated, the prevalences of 5 resistance mutations in P. falciparum dihydrofolate reductase (PfDHFR) and dihydropteroate synthase (PfDHPS) were nearly 100%, and the PfDHFR I164L and PfDHPS A581G mutations, associated with high-level resistance, had combined prevalence of 26.5%. The cumulative risks of recurrent parasitemia (SP 57.8%, DP 4.1%, DP + SP 3.9%), symptomatic malaria (SP 9.3%, DP 1.1%, DP + SP 0.3%), and recrudescent parasitemia (SP 40.1%, DP 2.0%, DP + SP 0.8%) were all significantly greater in the SP arm, with risks greatest in primigravidae. In the IPT-SP arm, the combined prevalence of the PfDHFR I164L and PfDHPS A581G mutations increased significantly from 24.9% at initiation of IPTp to 35.2% after receipt of IPTp-SP. Infection with mutant parasites was associated with non-significant increases in risks of recrudescence. Conclusions: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine had poor antimalarial preventive efficacy and selected for increased drug resistance, questioning the value of this intervention.
- 13 February 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (6) , 1110-1119
Recurrent Plasmodium falciparum Parasitemia and Drug Resistance Mutations During Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda
Background: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine (IPTp-SP) is recommended during pregnancy in malaria-endemic countries. However, widespread resistance of Plasmodium falciparum to SP has compromised its efficacy, and the alternative dihydroartemisinin-piperaquine (DP) is under study. Potential selection of drug resistance is important. Methods: We sequenced 1377 samples collected from pregnant women enrolled in a trial comparing monthly SP, DP, and DP + SP for IPTp in Busia, Uganda and with asymptomatic parasitemia at the time of IPTp administration. We characterized known markers of drug resistance and assessed the 28-day cumulative risk of recurrent parasitemia, with genotyping to distinguish recrudescence from new infections. Results: Among 771 samples collected on the day IPTp was initiated, the prevalences of 5 resistance mutations in P. falciparum dihydrofolate reductase (PfDHFR) and dihydropteroate synthase (PfDHPS) were nearly 100%, and the PfDHFR I164L and PfDHPS A581G mutations, associated with high-level resistance, had combined prevalence of 26.5%. The cumulative risks of recurrent parasitemia (SP 57.8%, DP 4.1%, DP + SP 3.9%), symptomatic malaria (SP 9.3%, DP 1.1%, DP + SP 0.3%), and recrudescent parasitemia (SP 40.1%, DP 2.0%, DP + SP 0.8%) were all significantly greater in the SP arm, with risks greatest in primigravidae. In the IPT-SP arm, the combined prevalence of the PfDHFR I164L and PfDHPS A581G mutations increased significantly from 24.9% at initiation of IPTp to 35.2% after receipt of IPTp-SP. Infection with mutant parasites was associated with non-significant increases in risks of recrudescence. Conclusions: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine had poor antimalarial preventive efficacy and selected for increased drug resistance, questioning the value of this intervention.
- Open Access
The Portable Microhaplotype Object and Tools
Structured Motivation: The rapid increase in the generation of targeted sequencing data offers immense potential for research, medicine, and public health, however the lack of an established standard for these data has led to disparate solutions for data storage. A widely accepted standard is essential for data sharing, reuse, and the coordinated development of interoperable analysis tools. Results: We propose the Portable Microhaplotype Object (PMO), a standardized format for efficiently and losslessly storing phased targeted sequencing data (microhaplotypes). The PMO format is JSON-based, allowing efficient, relational storage of genetic data together with relevant metadata to minimize orphaned data. The format includes required fields and a curated set of optional fields leveraging established ontologies. To facilitate ease of use, we developed pmotools-python, an open-source package for creating, manipulating, and exporting PMO data into common formats. Additionally, we provide a simple web-based app to quickly create PMO files from tabular inputs, making the format accessible to a wide variety of users. Example datasets from Plasmodium, Anopheles, Escherichia coli , and Staphylococcus aureus demonstrate the broad applicability of the approach. PMO will streamline data sharing, foster interoperability, and accelerate the development of harmonized analysis tools. Availability and implementation: The Portable Microhaplotype Object (PMO) project, including the ontology specification, software tools, example datasets, and tutorials, is freely available at https://plasmogenepi.github.io/PMO_Docs/ . Key software components and datasets have archived releases with DOIs to ensure permanence, detailed in the Supplementary Text 1-5. Contact: kathrynmmurie@gmail.com or nickjhathaway@gmail.com
Open AccessThe Portable Microhaplotype Object and Tools
Structured Motivation: The rapid increase in the generation of targeted sequencing data offers immense potential for research, medicine, and public health, however the lack of an established standard for these data has led to disparate solutions for data storage. A widely accepted standard is essential for data sharing, reuse, and the coordinated development of interoperable analysis tools. Results: We propose the Portable Microhaplotype Object (PMO), a standardized format for efficiently and losslessly storing phased targeted sequencing data (microhaplotypes). The PMO format is JSON-based, allowing efficient, relational storage of genetic data together with relevant metadata to minimize orphaned data. The format includes required fields and a curated set of optional fields leveraging established ontologies. To facilitate ease of use, we developed pmotools-python, an open-source package for creating, manipulating, and exporting PMO data into common formats. Additionally, we provide a simple web-based app to quickly create PMO files from tabular inputs, making the format accessible to a wide variety of users. Example datasets from Plasmodium, Anopheles, Escherichia coli , and Staphylococcus aureus demonstrate the broad applicability of the approach. PMO will streamline data sharing, foster interoperability, and accelerate the development of harmonized analysis tools. Availability and implementation: The Portable Microhaplotype Object (PMO) project, including the ontology specification, software tools, example datasets, and tutorials, is freely available at https://plasmogenepi.github.io/PMO_Docs/ . Key software components and datasets have archived releases with DOIs to ensure permanence, detailed in the Supplementary Text 1-5. Contact: kathrynmmurie@gmail.com or nickjhathaway@gmail.com
- Open Access
Recurrent Plasmodium falciparum parasitemia and drug resistance mutations during intermittent preventive treatment of malaria in pregnancy in Uganda
Background: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine (IPTp-SP) is recommended during pregnancy in malaria-endemic countries. However, widespread resistance of Plasmodium falciparum to SP has compromised its efficacy, and the alternative dihydroartemisinin-piperaquine (DP) is under study. Potential selection of drug resistance is of interest. Methods: We sequenced 1377 samples collected from pregnant women enrolled in a trial comparing monthly SP, DP, and DP+SP for IPTp in Busia, Uganda and with asymptomatic parasitemia at the time of IPTp administration. We characterized known markers of drug resistance and assessed the 28-day cumulative risk of recurrent parasitemia, with genotyping to distinguish recrudescence from new infections. Results: Among 771 samples collected on the day IPTp was initiated, the prevalences of five resistance mutations in P. falciparum dihydrofolate reductase (PfDHFR) and dihydropteroate synthase (PfDHPS) were nearly 100%, and the PfDHFR I164L and PfDHPS A581G mutations, associated with high-level resistance, had combined prevalence of 26.5%. The cumulative risks of recurrent parasitemia (SP 57.8%, DP 4.1%, DP+SP 3.9%), symptomatic malaria (SP 9.3%, DP 1.1%, DP+SP 0.3%), and recrudescent parasitemia (SP 40.1%, DP 2.0%, DP+SP 0.8%) were all significantly greater in the SP arm, with risks greatest in primigravidae. In the IPT-SP arm, the combined prevalence of the PfDHFR I164L and PfDHPS A581G mutations increased significantly from 24.9% at initiation of IPTp to 35.2% after receipt of IPTp-SP. Infection with mutant parasites was associated with non-significant increases in risks of recrudescence. Conclusions: IPTp-SP had poor preventive efficacy and selected for increased drug resistance, questioning the value of this intervention.
Open AccessRecurrent Plasmodium falciparum parasitemia and drug resistance mutations during intermittent preventive treatment of malaria in pregnancy in Uganda
Background: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine (IPTp-SP) is recommended during pregnancy in malaria-endemic countries. However, widespread resistance of Plasmodium falciparum to SP has compromised its efficacy, and the alternative dihydroartemisinin-piperaquine (DP) is under study. Potential selection of drug resistance is of interest. Methods: We sequenced 1377 samples collected from pregnant women enrolled in a trial comparing monthly SP, DP, and DP+SP for IPTp in Busia, Uganda and with asymptomatic parasitemia at the time of IPTp administration. We characterized known markers of drug resistance and assessed the 28-day cumulative risk of recurrent parasitemia, with genotyping to distinguish recrudescence from new infections. Results: Among 771 samples collected on the day IPTp was initiated, the prevalences of five resistance mutations in P. falciparum dihydrofolate reductase (PfDHFR) and dihydropteroate synthase (PfDHPS) were nearly 100%, and the PfDHFR I164L and PfDHPS A581G mutations, associated with high-level resistance, had combined prevalence of 26.5%. The cumulative risks of recurrent parasitemia (SP 57.8%, DP 4.1%, DP+SP 3.9%), symptomatic malaria (SP 9.3%, DP 1.1%, DP+SP 0.3%), and recrudescent parasitemia (SP 40.1%, DP 2.0%, DP+SP 0.8%) were all significantly greater in the SP arm, with risks greatest in primigravidae. In the IPT-SP arm, the combined prevalence of the PfDHFR I164L and PfDHPS A581G mutations increased significantly from 24.9% at initiation of IPTp to 35.2% after receipt of IPTp-SP. Infection with mutant parasites was associated with non-significant increases in risks of recrudescence. Conclusions: IPTp-SP had poor preventive efficacy and selected for increased drug resistance, questioning the value of this intervention.
- Open Access
Towards an open analysis ecosystem for Plasmodium genomic epidemiology
Major advances in Plasmodium sequencing approaches, bioinformatic pipelines, and data analysis tools have provided valuable insights into malaria epidemiology from parasite genomic data. However, translating genetic data into actionable information for decision-makers remains a challenge. Significant barriers limit the integration of these advances into a functional data analysis ecosystem that produces standardized, interpretable results for use by national malaria control programs. The Plasmodium Genomic Epidemiology (PlasmoGenEpi) network convened 18 subject matter experts across 15 institutions at the R eproducibility, A ccessibility, D ocumentation, and I nteroperability S tandards H ackathon in 20 23 (RADISH23) to identify available analysis tools, evaluate software standards, improve documentation, and outline workflows. Eight use cases for genomic data were identified, and a subset were developed into analysis workflows in terms of a series of connected functionalities. Software tools were then mapped against functionalities to outline a modular approach to data analysis for these use cases. In addition to outlining workflows, a set of objective criteria were developed for evaluating software standards. Forty Plasmodium genomic analysis tools were identified, of which 22 were prioritized for software standards evaluation. Additional tutorials were developed for 10 tools in the form of reproducible code applied to shared datasets. These resources are available on PGEforge ( mrc- ide.github.io/PGEforge ), a new community resource that serves as a central, open repository for current and future resources for malaria genomic data analysis.
Open AccessTowards an open analysis ecosystem for Plasmodium genomic epidemiology
Major advances in Plasmodium sequencing approaches, bioinformatic pipelines, and data analysis tools have provided valuable insights into malaria epidemiology from parasite genomic data. However, translating genetic data into actionable information for decision-makers remains a challenge. Significant barriers limit the integration of these advances into a functional data analysis ecosystem that produces standardized, interpretable results for use by national malaria control programs. The Plasmodium Genomic Epidemiology (PlasmoGenEpi) network convened 18 subject matter experts across 15 institutions at the R eproducibility, A ccessibility, D ocumentation, and I nteroperability S tandards H ackathon in 20 23 (RADISH23) to identify available analysis tools, evaluate software standards, improve documentation, and outline workflows. Eight use cases for genomic data were identified, and a subset were developed into analysis workflows in terms of a series of connected functionalities. Software tools were then mapped against functionalities to outline a modular approach to data analysis for these use cases. In addition to outlining workflows, a set of objective criteria were developed for evaluating software standards. Forty Plasmodium genomic analysis tools were identified, of which 22 were prioritized for software standards evaluation. Additional tutorials were developed for 10 tools in the form of reproducible code applied to shared datasets. These resources are available on PGEforge ( mrc- ide.github.io/PGEforge ), a new community resource that serves as a central, open repository for current and future resources for malaria genomic data analysis.
- Open Access
- 7 October 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Interchromosomal segmental duplication drives translocation and loss of P. falciparum histidine-rich protein 3
Most malaria rapid diagnostic tests (RDTs) detect Plasmodium falciparum histidine-rich protein 2 (PfHRP2) and PfHRP3, but deletions of pfhrp2 and phfrp3 genes make parasites undetectable by RDTs. We analyzed 19,313 public whole-genome-sequenced P. falciparum field samples to understand these deletions better. Pfhrp2 deletion only occurred by chromosomal breakage with subsequent telomere healing. Pfhrp3 deletions involved loss from pfhrp3 to the telomere and showed three patterns: no other associated rearrangement with evidence of telomere healing at breakpoint (Asia; Pattern 13-TARE1); associated with duplication of a chromosome 5 segment containing multidrug-resistant-1 gene (Asia; Pattern 13-5++); and most commonly, associated with duplication of a chromosome 11 segment (Americas/Africa; Pattern 13-11++). We confirmed a 13–11 hybrid chromosome with long-read sequencing, consistent with a translocation product arising from recombination between large interchromosomal ribosome-containing segmental duplications. Within most 13-11++ parasites, the duplicated chromosome 11 segments were identical. Across parasites, multiple distinct haplotype groupings were consistent with emergence due to clonal expansion of progeny from intrastrain meiotic recombination. Together, these observations suggest negative selection normally removes 13-11++pfhrp3 deletions, and specific conditions are needed for their emergence and spread including low transmission, findings that can help refine surveillance strategies.
- 7 October 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessInterchromosomal segmental duplication drives translocation and loss of P. falciparum histidine-rich protein 3
Most malaria rapid diagnostic tests (RDTs) detect Plasmodium falciparum histidine-rich protein 2 (PfHRP2) and PfHRP3, but deletions of pfhrp2 and phfrp3 genes make parasites undetectable by RDTs. We analyzed 19,313 public whole-genome-sequenced P. falciparum field samples to understand these deletions better. Pfhrp2 deletion only occurred by chromosomal breakage with subsequent telomere healing. Pfhrp3 deletions involved loss from pfhrp3 to the telomere and showed three patterns: no other associated rearrangement with evidence of telomere healing at breakpoint (Asia; Pattern 13-TARE1); associated with duplication of a chromosome 5 segment containing multidrug-resistant-1 gene (Asia; Pattern 13-5++); and most commonly, associated with duplication of a chromosome 11 segment (Americas/Africa; Pattern 13-11++). We confirmed a 13–11 hybrid chromosome with long-read sequencing, consistent with a translocation product arising from recombination between large interchromosomal ribosome-containing segmental duplications. Within most 13-11++ parasites, the duplicated chromosome 11 segments were identical. Across parasites, multiple distinct haplotype groupings were consistent with emergence due to clonal expansion of progeny from intrastrain meiotic recombination. Together, these observations suggest negative selection normally removes 13-11++pfhrp3 deletions, and specific conditions are needed for their emergence and spread including low transmission, findings that can help refine surveillance strategies.